|
Risk factors
|
Univariate
|
Multivariate
|
|---|
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Age (years)
|
0.123
| | |
|
Gender
|
0.870
| | |
|
Total bilirubin (mg/dL)
|
0.033
|
1.312 (0.943–1.825)
|
0.108
|
|
Platelet (× 103/mL)
|
0.342
| | |
|
Albumin (g/dL)
|
0.556
| | |
|
PT (%)
|
0.153
| | |
|
AFP (ng/mL)
|
0.446
| | |
|
PIVKA-II (m AU/mL)
|
0.205
| | |
|
Tumor size
|
0.446
| | |
|
Tumor number
|
0.105
| | |
|
Previous locoregional treatment
|
0.528
| | |
|
PVTT
|
0.407
| | |
|
Extrahepatic metastasis
|
0.595
| | |
|
HAIC cycle
|
0.119
| | |
|
Liver resection after HAIC
|
0.001
|
3.480 (1.587-7.630)
|
0.002
|
- HAIC hepatic arterial infusion chemotherapy, HR hazard ratio, CI, confidence interval, PT prothrombin time, AFP alpha-fetoprotein, PIVKA-II proteins induced by vitamin K antagonist-II, PVTT portal vein tumor thrombus, ORR objective response rate
